ContraFect (NASDAQ:CFRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of ContraFect (NASDAQ:CFRXGet Rating) in a report released on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, SVB Leerink reduced their target price on ContraFect from $14.00 to $9.00 and set an “outperform” rating on the stock in a report on Wednesday, February 16th.

CFRX stock opened at $4.28 on Tuesday. The business has a fifty day moving average price of $3.49 and a 200 day moving average price of $3.28. The stock has a market capitalization of $168.35 million, a price-to-earnings ratio of -7.64 and a beta of 0.57. ContraFect has a fifty-two week low of $2.11 and a fifty-two week high of $4.76.

ContraFect (NASDAQ:CFRXGet Rating) last released its earnings results on Thursday, March 24th. The biotechnology company reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.13. As a group, equities research analysts forecast that ContraFect will post -1.19 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of CFRX. 683 Capital Management LLC lifted its position in shares of ContraFect by 24.6% during the 3rd quarter. 683 Capital Management LLC now owns 823,964 shares of the biotechnology company’s stock worth $3,337,000 after buying an additional 162,732 shares in the last quarter. Moody Lynn & Lieberson LLC purchased a new stake in shares of ContraFect during the 4th quarter worth approximately $26,000. WealthTrust Axiom LLC grew its stake in ContraFect by 20.0% in the 4th quarter. WealthTrust Axiom LLC now owns 30,025 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 5,000 shares in the last quarter. Transcend Wealth Collective LLC purchased a new position in ContraFect in the 3rd quarter valued at approximately $83,000. Finally, Dimensional Fund Advisors LP purchased a new position in ContraFect in the 3rd quarter valued at approximately $86,000. Hedge funds and other institutional investors own 58.44% of the company’s stock.

ContraFect Company Profile (Get Rating)

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia.

Featured Articles

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.